DCM
ANRO icon

Driehaus Capital Management’s Alto Neuroscience ANRO Stock Holding History

Driehaus Capital Management’s Portfolio ANRO Stock Details ANRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.9M Buy
487,576
+850
+0.2% +$19.7K 0.07% 264
2026
Q1 		$10.9M Buy
486,726
+149,964
+45% +$2.78M 0.08% 264
2025
Q4 		$5.99M Buy
+336,762
New +$4.24M 0.04% 301

Other funds holding ANRO

AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SSC
Spruce Street Capital New York $510M AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Driehaus Capital Management's ANRO Position: Q2 2026 in Review

Driehaus Capital Management increased its Alto Neuroscience (ANRO) stake by 0.17% in Q2 2026, buying an estimated $19.7K and bringing the position to 487,576 shares worth $12.9M. The position accounts for 0.07% of the portfolio, ranked #264.

Driehaus Capital Management first reported a position in ANRO in Q4 2025 and has held it in 3 quarters since. 114 funds tracked by Wall St. Rank hold ANRO as of Q2 2026.

  • Driehaus Capital Management held 487,576 shares of Alto Neuroscience worth $12.9M as of Q2 2026.
  • Driehaus Capital Management bought 850 Alto Neuroscience shares in Q2 2026, an estimated $19.7K.
  • Alto Neuroscience made up 0.07% of Driehaus Capital Management's portfolio in Q2 2026, its #264 holding.
  • Driehaus Capital Management first reported a position in Alto Neuroscience in Q4 2025 and has held it in 3 quarters since.
  • 114 funds tracked by Wall St. Rank held Alto Neuroscience as of Q2 2026.

Based on Driehaus Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.